Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Core One Labs Inc. C.COOL

Alternate Symbol(s):  CLABF

Healthcare Cannabis
Core One Labs Inc. is a Canada-based life sciences biotechnology research and development company. The Company is focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of delivery systems technology. The Company, through its wholly owned subsidiary, Vocan... see more

Recent & Breaking News (CSE:COOL)

Core One Labs Inc. Announces Initial Agreement for Potential Sale of Proprietary Biosynthetic Psilocybin, Facilitating Entry into the International Market

Accesswire December 8, 2023

Core One Labs' Akome Reveals Impressive Results for its Psychedelic Bio-Compounds Designed to Target Alzheimer's and Parkinson's, Showing Potential to Outperform Current Treatment Methods

Accesswire December 1, 2023

Core One's Akome Reveals Groundbreaking Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer's and Parkinson's Disease

Accesswire August 4, 2023

Core One Labs', Awakened Biosciences, Announces Groundbreaking Step Forward in Isolating and Purifying Psilocybin from Mushroom Biomass

Accesswire August 1, 2023

Core One's Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer's and Parkinson's Disease

Accesswire July 28, 2023

Core One Labs Enters into Letter of Intent for First Sale of Its Psychedelic Compounds

Accesswire July 21, 2023

Core One's Vocan Biotechnologies Incorporates New Bioreactor Equipment into Production Process Significantly Increasing Throughput of Proprietary Biosynthetic Psilocybin

Accesswire July 11, 2023

Core One's Vocan Files International Patent for its Breakthrough Proprietary Biosynthetic Psilocybin Production Method

Accesswire July 7, 2023

Core One in Talks with Multiple Companies to Supply Psilocybin

Accesswire May 5, 2023

Core One Labs' GMP Drug Takes Further Steps Toward Commercialization: Initiating Development of Psychedelic Prodrugs with Long-established Compounding Pharmacy

Accesswire May 1, 2023

Core One's Awakened Completes Successful Synthetic Production of Psilocin in its GMP Certified Manufacturing Facility

Accesswire April 21, 2023

Core One Labs' Akome Signs Contract with University of Barcelona: Initiating Animal Model Studies on Psychedelics Drug Development to Combat a Variety of Neurological Diseases

Accesswire January 24, 2023

Core One Labs' Acquires GMP Drug Inc.: Positioning Itself as a Full Cycle Psychedelics Supply Chain Solution for Clinicians, Researchers and Other Drug Developers

Accesswire January 13, 2023

Core One Labs' Prepares for Commercial Production of API-Grade Psilocybin; Plans Initial Production Run at GMP Facility in January

Accesswire November 18, 2022

Core One Labs Takes Next Steps to Prepare for Potential Takeover Opportunities

Accesswire October 21, 2022

European University to Fund Core One Labs' Akome Advanced Neurogenesis Stimulation Studies

Accesswire October 14, 2022

Core One Labs Nearing GMP Production as Canada's Province of Alberta Announces Game Changing Legislation

Accesswire October 7, 2022

Core One Labs Announces Breakthrough with Proprietary Isolation and Purification Method of Psilocybin from Mushrooms; Prepares Patent Application

Accesswire September 30, 2022

Core One Labs Signs Letter of Intent with GMP Manufacturing Partner for Production of Proprietary Psychedelic Compounds

Accesswire September 23, 2022

Core One Labs' Akome Move Psychedelic Drug Formulations to Next Stage of Development: Initiating Phase 2 Analysis of Therapeutic Potential

Accesswire September 16, 2022